Terumo : 3rd Quarter Financial Results for FYE 3/2022(354.2 KB)

February 9, 2022

Consolidated Financial Results

for the Third Quarter Ended December 31, 2021

Terumo Corporation〔IFRS〕

Company name:	TERUMO CORPORATION
Listing:	Tokyo Stock Exchange
Securities code:	4543
URL:	https://www.terumo.com/
Representative:	Shinjiro Sato, President and CEO
Inquiries:	Kenichi Hata, General Manager, Investor Relations Dept.
Telephone:	[phone]

Scheduled date to file quarterly securities report:	February 14, 2022
Scheduled date to commence dividend payments:	－
Preparation of supplementary material on quarterly financial results: Yes
Holding of quarterly financial results briefing:	Yes (for Securities analysts, Institutional
	investors)

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the nine months ended December 31, 2021 (from April 1, 2021 to December 31, 2021)

(1) Consolidated operating results (cumulative)					(Percentages indicate year-on-year changes.)
															Profit for the		Profit attributable	Total
			Revenue		Operating profit	Profit before tax		comprehensive
				period			to owners of
																	income
																			parent
	Nine months ended		Millions of	%		Millions of	%	Millions of		%	Millions of	%		Millions of	%	Millions of		%
			yen				yen		yen					yen				yen		yen
	December 31,	523,482	16.7		94,455	25.5	93,044		24.2	71,696	22.6		71,696	22.3	102,045			182.9
	2021
	December 31,	448,628	(4.6)		75,272	(12.7)	74,928		(12.4)	58,502	(12.4)		58,601	(12.4)	36,077			(36.4)
	2020
			Basic earnings			Diluted earnings
			per share				per share
	Nine months ended					Yen				Yen
	December 31,			94.82				94.76
	2021
	December 31,			77.63				77.44
	2020
(Note) Adjusted operating profit December 2021: 107,157 million yen	December 2020: 88,489 million yen
(2) Consolidated financial position
														Equity attributable to		Ratio of equity
			Total assets				Total equity				attributable to owners of
									owners of parent
																parent to total assets
	As of			Millions of yen			Millions of yen		Millions of yen			%
	December 31, 2021			1,401,522			935,904			935,904			66.8
	March 31, 2021			1,351,192			856,662			856,662			63.4

－ 1 －

2. Cash dividends

		Annual dividends per share
	First quarter-end	Second quarter-end		Third quarter-end		Fiscal year-end	Total
	Yen	Yen		Yen		Yen	Yen
Fiscal year ended	－	14.00		－		15.00	29.00
March 31, 2021
Fiscal year ending	－	16.00		－
March 31, 2022
Fiscal year ending
March 31, 2022						16.00	32.00
(Forecast)

(Note) Revision from the dividend forecast, which is published in the most recent: None

3. Consolidated Forecast for the Fiscal Year Ending March, 2022 (From April 1, 2021 to March 31, 2022) (Percentages indicate year-on-year changes.)

				Adjusted operating			Profit for the year	Basic earnings per
	Revenue		Operating profit	attributable to owners
		profit		share
							of parent
Fiscal Year ending	Millions of yen		%	Millions of yen	%	Millions of yen	%	Millions of yen		%	Yen
March, 2022	697,000		13.5	137,000	18.2	120,000	22.0	92,000		19.1	121.66

(Note) Revision of forecast for fiscal year ending March, 2022: Yes

Regarding the forecast for cumulative consolidated earnings for the fiscal year, please refer to the February 9th, 2022 press release "Terumo Revises its Full-Year Financial Guidance for FY2021".

Basic earnings per share is calculated by taking into consideration effects of the conversion of convertible bonds in the nine months.

• Assumed exchange rate for fiscal year ending March, 2022: USD1=112JPY, EUR1=130JPY

－ 2 －

[Terumo Corporation] Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2022

*Notes

(1) Changes in significant subsidiaries during the current quarterly consolidated cumulative period (changes in specified subsidiaries resulting in changes in the scope of consolidation): None

New － Company (Company Name) －, Excluded － Company (Company Name) －

1. Changes in accounting policies and changes in accounting estimates

1. Changes in accounting policies required by IFRS: None
2. Changes in accounting policies other than (i): None
3. Changes in accounting estimates: None

1. Number of outstanding shares (common stock)

1. Number of outstanding shares at the end of the period (including treasury shares)
2. Treasury shares at the end of the period
3. Average number of shares during the period (cumulative quarterly)

As of December 31,	759,521,040 shares	As of March 31, 2021	759,521,040 shares
2021
As of December 31,	3,203,152 shares	As of March 31, 2021	3,508,047 shares
2021
Nine months ended	756,170,427 shares	Nine months ended	754,856,119 shares
December 31, 2021		December 31, 2020

*Quarterly financial statements are not subject to quarterly reviews by certified accountants or audit firms.

*Explanation on appropriate use of financial results forecasts and other special notes

1. Forward-lookingstatements, including earnings forecasts, contained in these disclosure materials are based on currently available information and assumptions believed to be reasonable by management. This is not a promise or guarantee by Terumo that it will achieve these goals. In addition, actual results may differ significantly due to several factors. For the assumptions that are the premise of the earnings forecast and the precautions for using the earnings forecast, refer to [Attachment], page 8, "1. Overview of Financial Results for the First Nine Months of the Fiscal Year Ending March 31, 2022 (3) Forecasts, including the Consolidated Financial Results for the Fiscal Year Ending March 31, 2022".
2. Adjusted operating profit factors out amortization expense for intangible assets obtained during acquisitions and one-off income and expenses from operating profit. In addition, adjusted operating profit is consistent with segment profit. We are disclosing adjusted operating profit as we are using it as a performance indicator.

－ 3 －

[Terumo Corporation] Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2022
 Table of contents of attached materials
1. Overview of Financial Results for the First Nine Months of the Fiscal Year Ending March 31, 2022 ..................	5
(1)	Overview of Consolidated Business Results......................................................................................................	5
(2)	Overview of Consolidated Statement of Financial Position ..............................................................................	8
(3)	Forecasts, including the Consolidated Financial Results for the Fiscal Year Ending March 31, 2022 ..............	8
2. Condensed Consolidated Financial Statements ......................................................................................................	9
(1)	Condensed Consolidated Statement of Financial Position.................................................................................	9
(2)	Condensed Consolidated Statement of Profit or Loss and Condensed Consolidated Statement of
	Comprehensive Income ...............................................................................................................................	11
(3)	Condensed Consolidated Statement of Change in Equity ..............................................................................	13
(4)	Notes Pertaining to Condensed Consolidated Financial Statements ................................................................	13
(i) Going Concern Assumption .........................................................................................................................	13
(ii) Segment information ..................................................................................................................................	14

－ 4 －

[Terumo Corporation] Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2022

1. Overview of Financial Results for the First Nine Months of the Fiscal Year Ending March 31, 2022

(1) Overview of Consolidated Business Results

In the first nine months of the current fiscal year (from April 1, 2021 to December 31, 2021), the Group's sales were generally strong amid the ongoing recovery trend in medical demand from the impacts of the COVID-19 pandemic experienced in the first three months of the current fiscal year. However, the problems of inflation on manufacturing cost and lower capacity utilization in factories along with supply chain disruptions seen across all industries and regions have begun to affect the Group as well. The Group will need to continue finding ways to secure stable supplies of these resources from the fourth quarter into next fiscal year.

Financial results for the first nine months are as follows:

			(Unit: Millions of yen)
	For the nine	For the nine		Growth
	months ended	months ended	Growth (%)	excluding impact
	December 31,	December 31,	of FX
	2020	2021		translations (%)
Revenue	448,628	523,482	16.7	11.9
Gross profit	241,268	278,841	15.6	10.2
Adjusted operating profit	88,489	107,157	21.1	13.3
Operating profit	75,272	94,455	25.5	16.9
Profit before tax	74,928	93,044	24.2	－
Profit for the period	58,502	71,696	22.6	－
Profit for the period
attributable to owners of	58,601	71,696	22.3	－
parent

Revenue by geographic areas for the first nine months is as follows:

			(Unit: Millions of yen)
	For the nine	For the nine		Growth
Geographic areas	months ended	months ended	Growth (%)	excluding impact
December 31,	December 31,	of FX
	2020	2021		translations (%)
Japan	148,349	155,034	4.5	4.5
Europe	87,547	103,997	18.8	11.2
Americas	131,132	161,219	22.9	17.2
Asia and others	81,598	103,231	26.5	17.6
Overseas total	300,279	368,447	22.7	15.5
Total	448,628	523,482	16.7	11.9

－ 5 －